Stock 4521 KAKEN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Kaken Pharmaceutical Co., Ltd.

Equities

4521

JP3207000005

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-04-26 am EDT 		5-day change 1st Jan Change
3,407 JPY +0.53% Intraday chart for Kaken Pharmaceutical Co., Ltd. -0.21% +1.55%
2023 Kaken Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for Fiscal Year Ending March 31, 2024 CI
2023 Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Final dividend
FA
Kaken Pharmaceutical Co., Ltd. Declares Dividend for the Second Quarter of Fiscal Ending March 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Full Year Ending March 31, 2024
CI
Kaken Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for Fiscal Year Ending March 31, 2024
CI
Kaken Pharmaceutical : Presentation material for meeting
PU
Kaken Pharmaceutical : Reference Data of Financial Statements for the 2Q of Fiscal 2023
PU
Kaken Pharmaceutical : Corporate Report 2023
PU
Ex-dividend day for interim dividend
FA
Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index
CI
Kaken Pharmaceutical’s Attributable Profit Drops 13.7% in Fiscal Q1 due to Higher Expenses
MT
Kaken Pharmaceutical Co., Ltd. Provides Dividend Forecast for Second Quarter of 2024 and Fiscal Year Ending March 31, 2024
CI
Kaken Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for Fiscal Year Ending March 31, 2024
CI
Kaken Pharmaceutical : Reference Data of Consolidated Financial Results for 1st Quarter of Fiscal 2023
PU
MediWound Announces Commercial Launch of NexoBrid in Japan
AQ
MediWound Partner Launches NexoBrid in Japan
MT
Botanix Pharmaceuticals Partner Secures Sublicense, Distribution Deal in Korea
MT
Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program
AQ
Kaken Pharmaceutical : Presentation material for meeting
PU
Kaken Pharmaceutical : Reference Data of Financial Statements Fiscal 2022
PU
Kaken Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023
CI
Kaken Pharmaceutical : Consolidated Financial Results for the Fiscal 2022
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4521 Stock
  4. News Kaken Pharmaceutical Co., Ltd.